These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

882 related articles for article (PubMed ID: 19293183)

  • 21. SMAD4 mediates mesenchymal-epithelial reversion in SW480 colon carcinoma cells.
    Pohl M; Radacz Y; Pawlik N; Schoeneck A; Baldus SE; Munding J; Schmiegel W; Schwarte-Waldhoff I; Reinacher-Schick A
    Anticancer Res; 2010 Jul; 30(7):2603-13. PubMed ID: 20682989
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Autocrine production of TGF-beta confers resistance to apoptosis after an epithelial-mesenchymal transition process in hepatocytes: Role of EGF receptor ligands.
    Del Castillo G; Murillo MM; Alvarez-Barrientos A; Bertran E; Fernández M; Sánchez A; Fabregat I
    Exp Cell Res; 2006 Sep; 312(15):2860-71. PubMed ID: 16828470
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulation of extracellular matrix remodeling following transforming growth factor-beta1/epidermal growth factor-stimulated epithelial-mesenchymal transition in human premalignant keratinocytes.
    Wilkins-Port CE; Higgins PJ
    Cells Tissues Organs; 2007; 185(1-3):116-22. PubMed ID: 17587817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resveratrol inhibits TGF-β1-induced epithelial-to-mesenchymal transition and suppresses lung cancer invasion and metastasis.
    Wang H; Zhang H; Tang L; Chen H; Wu C; Zhao M; Yang Y; Chen X; Liu G
    Toxicology; 2013 Jan; 303():139-46. PubMed ID: 23146760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer.
    Buijs JT; Henriquez NV; van Overveld PG; van der Horst G; Que I; Schwaninger R; Rentsch C; Ten Dijke P; Cleton-Jansen AM; Driouch K; Lidereau R; Bachelier R; Vukicevic S; Clézardin P; Papapoulos SE; Cecchini MG; Löwik CW; van der Pluijm G
    Cancer Res; 2007 Sep; 67(18):8742-51. PubMed ID: 17875715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. nm23-H1 is a negative regulator of TGF-β1-dependent induction of epithelial-mesenchymal transition.
    Zhao R; Gong L; Li L; Guo L; Zhu D; Wu Z; Zhou Q
    Exp Cell Res; 2013 Mar; 319(5):740-9. PubMed ID: 23137649
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inability of transforming growth factor-beta to cause SnoN degradation leads to resistance to transforming growth factor-beta-induced growth arrest in esophageal cancer cells.
    Edmiston JS; Yeudall WA; Chung TD; Lebman DA
    Cancer Res; 2005 Jun; 65(11):4782-8. PubMed ID: 15930298
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential.
    Fritzmann J; Morkel M; Besser D; Budczies J; Kosel F; Brembeck FH; Stein U; Fichtner I; Schlag PM; Birchmeier W
    Gastroenterology; 2009 Jul; 137(1):165-75. PubMed ID: 19328798
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells.
    Deckers M; van Dinther M; Buijs J; Que I; Löwik C; van der Pluijm G; ten Dijke P
    Cancer Res; 2006 Feb; 66(4):2202-9. PubMed ID: 16489022
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TGF-beta1 causes epithelial-mesenchymal transition in HaCaT derivatives, but induces expression of COX-2 and migration only in benign, not in malignant keratinocytes.
    Räsänen K; Vaheri A
    J Dermatol Sci; 2010 May; 58(2):97-104. PubMed ID: 20399617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression.
    Huber MA; Azoitei N; Baumann B; Grünert S; Sommer A; Pehamberger H; Kraut N; Beug H; Wirth T
    J Clin Invest; 2004 Aug; 114(4):569-81. PubMed ID: 15314694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FMNL2 enhances invasion of colorectal carcinoma by inducing epithelial-mesenchymal transition.
    Li Y; Zhu X; Zeng Y; Wang J; Zhang X; Ding YQ; Liang L
    Mol Cancer Res; 2010 Dec; 8(12):1579-90. PubMed ID: 21071512
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decreased expression of glutaredoxin 1 is required for transforming growth factor-beta1-mediated epithelial-mesenchymal transition of EpRas mammary epithelial cells.
    Lee EK; Jeon WK; Chae MY; Hong HY; Lee YS; Kim JH; Kwon JY; Kim BC; Park SH
    Biochem Biophys Res Commun; 2010 Jan; 391(1):1021-7. PubMed ID: 19968960
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncogenic function of a novel WD-domain protein, STRAP, in human carcinogenesis.
    Halder SK; Anumanthan G; Maddula R; Mann J; Chytil A; Gonzalez AL; Washington MK; Moses HL; Beauchamp RD; Datta PK
    Cancer Res; 2006 Jun; 66(12):6156-66. PubMed ID: 16778189
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rho activation is required for transforming growth factor-beta-induced epithelial-mesenchymal transition in lens epithelial cells.
    Cho HJ; Yoo J
    Cell Biol Int; 2007 Oct; 31(10):1225-30. PubMed ID: 17537651
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transforming growth factor-beta induces epithelial to mesenchymal transition by down-regulation of claudin-1 expression and the fence function in adult rat hepatocytes.
    Kojima T; Takano K; Yamamoto T; Murata M; Son S; Imamura M; Yamaguchi H; Osanai M; Chiba H; Himi T; Sawada N
    Liver Int; 2008 Apr; 28(4):534-45. PubMed ID: 18031476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. alpha2HS-glycoprotein, an antagonist of transforming growth factor beta in vivo, inhibits intestinal tumor progression.
    Swallow CJ; Partridge EA; Macmillan JC; Tajirian T; DiGuglielmo GM; Hay K; Szweras M; Jahnen-Dechent W; Wrana JL; Redston M; Gallinger S; Dennis JW
    Cancer Res; 2004 Sep; 64(18):6402-9. PubMed ID: 15374947
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of E-cadherin-dependent and -independent events in a new model of c-Fos-mediated epithelial-mesenchymal transition.
    Mejlvang J; Kriajevska M; Berditchevski F; Bronstein I; Lukanidin EM; Pringle JH; Mellon JK; Tulchinsky EM
    Exp Cell Res; 2007 Jan; 313(2):380-93. PubMed ID: 17141758
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Epithelial-mesenchymal transition in cancer progression].
    Gos M; Miłoszewska J; Przybyszewska M
    Postepy Biochem; 2009; 55(2):121-8. PubMed ID: 19824467
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epithelial-mesenchymal transition in ovarian cancer.
    Vergara D; Merlot B; Lucot JP; Collinet P; Vinatier D; Fournier I; Salzet M
    Cancer Lett; 2010 May; 291(1):59-66. PubMed ID: 19880243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.